Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study

summary of:
Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study
Vet in the clinic examine with stethoscope a dog breed Yorkshire terrier
B. Besche, T. Blondel, E. Guillot, C. Garelli‐Paar and M.A. Oyama
Published in:
September 2020
Type of access:

Open access

In our edition of: Oct 2020
In our categories of: small animals

our summary:

Besche, B. et al. (2020) Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study. Journal of Veterinary Internal Medicine, 34 (5), pp. 1746– 1758

The aim of this blinded, randomised, non-inferiority study was to evaluate the efficacy and safety of torasemide, compared to furosemide, in dogs with congestive heart failure (CHF) caused by degenerative mitral valve disease (DMVD).

The study, which was sponsored by Ceva, was carried out at 46 private veterinary practices in seven European countries between February 2013 and December 2015. Dogs were included if they had first-time CHF caused by DMVD. Eligible dogs were randomly assigned to one of two treatments, once-daily torasemide or twice-daily furosemide, with dosage based on set criteria. The main investigator on each site was blinded to treatment group and the animal owner was blinded as to which drug was given once versus twice daily. Dogs were examined at five time points: Day 0 (D0), Day 4 (D4), Day 14 (D14), Day 42 (D42) and Day 84 (D84) (± 3 days).

The primary efficacy criterion was treatment success at D14, with success defined as lowering of both radiographic pulmonary oedema and clinical cough scores, and no worsening of both dyspnoea and exercise intolerance scores, both compared to D0. Secondary efficacy and safety criteria included treatment response at D84, frequency of adverse events, owner compliance to the treatment regime, time to cardiac-related death or euthanasia or need to adjust treatment during the first 14 days.

The study population consisted of a total of 315 dogs, of which 159 received torasemide and 156 furosemide. Twenty dogs in each treatment group were excluded between D0 and D14, resulting in 275 dogs per protocol set one (PP1) (D14) analysis. An additional 32 dogs in the torasemide group and 26 in the furosemide group were removed between D14 and D84, leaving 217 dogs in the PP2 (D84) set.

There was no significant difference between the percentages of dogs that met the primary efficacy criterion at D14. The primary and secondary endpoints in both the PP1 and PP2 yielded similar results, thus torasemide was non inferior to furosemide at both D14 and D84. A significantly higher percentage of dogs receiving furosemide were prematurely withdrawn from the study and a significant difference was found in time to endpoint between treatment groups. No significant difference was found between treatment groups in the percentage of dogs experiencing serious adverse events. A higher percentage of owners administering torasemide achieved treatment compliance in D0–D14 compared to those administering furosemide, treatment compliance from D0 to D84 was >98% in both groups.

Limitations of the study included the short follow-up time, the study involved different veterinarians at practices in seven countries, and diagnostic results were not subject to review by a central committee.

Take Home

In this study, torasemide was shown to be non-inferior (no worse) than furosemide in treating first time CHF caused by DMVD. Further studies looking at the long-term efficacy and safety of torasemide are encouraged.

Image copyright attribute: kukota 

Join the discussion

We encourage discussion on all material highlighted in each edition of inFOCUS. Use the button below to join the conversation on Twitter and include your comment in the feed for this issue.

Twitter feed is not available at the moment.
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.